News | Radiation Therapy | February 13, 2020

ASTRO Awarded Contract from VA to Develop Measures on Quality of Radiation Therapy Services

The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from the U.S. Department of Veterans Affairs (VA) to develop quality indicators (QI) for radiation treatments provided to veterans with head and neck, breast and gastrointestinal cancers

February 13, 2020 — The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from the U.S. Department of Veterans Affairs (VA) to develop quality indicators (QI) for radiation treatments provided to veterans with head and neck, breast and gastrointestinal cancers.

“This pioneering effort leverages evidence-based guidelines and the consensus of medical experts in a new and powerful way to optimize care for military veterans,” said Theodore L. DeWeese, M.D., FASTRO, Chair of the ASTRO Board of Directors. “VA’s leadership in this area is impressive. ASTRO is honored to work with VA in this effort to promote high quality care to our nation’s veterans.”

More than 16,000 veterans receive radiation oncology care through 40 VA clinics nationwide each year. The new metrics will support the VA Radiation Oncology Quality Surveillance program (VA-ROQS), which was established to standardize and improve services at these facilities. Recently, ASTRO partnered with VA to establish QI for lung and prostate cancers forming the evidence basis for the VA-ROQS program.

The goal of VA-ROQS is to combine information technology with clinical expertise to provide physicians with real-time, evidence-based feedback on areas of quality-related performance. Data gathered from these QI, such as radiation dosing or treatment delivery, can then be used by VA-ROQS for quality assessments that show how an individual case scores against national benchmarks and other VA practitioners. The VA-ROQS program allows VA physicians to pinpoint areas for improvement and make meaningful adjustments in their patient care.

ASTRO previously worked with VA and Washington University on the national Radiation Oncology Practice Assessment (ROPA) program. ROPA, the pilot study for VA-ROQS, created the methodology and IT infrastructure while providing comprehensive QI for VA radiation oncologists treating patients with prostate or lung cancers. From 2016 to 2018, the program evaluated more than 1,500 patient cases across the 40 VA facilities, and a recent analysis indicates that from the outset more than 80% of these cases met or exceeded quality standards.

For more information: www.astro.org

Related Content

"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...